Brandon Kai, MD
Interventional Cardiology · Honolulu, HINPI 1285913632
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.2%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Edwards Lifesciences at 37.3% of the total.
Across 48 payments — averaging $65.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$1K
- Medtronic$461
- Boehringer Ingelheim$362
- W. L. Gore & Associates, Inc.$315
- AstraZeneca$249
- Vapotherm Inc$124
- plus $472 from 9 others
What the payments were for
- Consulting fees$44014%
- Speaking & faculty fees$31510%
- Travel & lodging$94730%
- Food & beverage$1,46346%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 13 | $1,180 |
| Medtronic | 2 | $461 |
| Boehringer Ingelheim | 10 | $362 |
| W. L. Gore & Associates, Inc. | 1 | $315 |
| AstraZeneca | 2 | $249 |
| Vapotherm Inc | 1 | $124 |
| Lantheus Medical Imaging, Inc. | 5 | $114 |
| Shockwave Medical, Inc | 3 | $81 |
| Boston Scientific | 4 | $81 |
| E.r. Squibb & Sons, L.L.C. | 2 | $60 |
| Cvrx, Inc. | 1 | $38 |
| Bayer | 1 | $32 |
| Pfizer | 1 | $24 |
| Abiomed | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EXPORT AP$440
- Product in Development$315
- FARXIGA$249
- VAPOTHERM$124
- JARDIANCE$111
How this compares
Too few interventional cardiology providers in Hawaiito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 961 | $967,309 |
| EntrestoSacubitril/Valsartan | 199 | $227,489 |
| FarxigaDapagliflozin Propanediol | 101 | $95,925 |
| JardianceEmpagliflozin | 94 | $94,683 |
| XareltoRivaroxaban | 67 | $74,686 |
| Repatha SureclickEvolocumab | 61 | $34,690 |
| BrilintaTicagrelor | 24 | $20,153 |
| Atorvastatin Calcium | 341 | $11,398 |
| Repatha PushtronexEvolocumab | 16 | $9,837 |
| Metoprolol Succinate | 582 | $9,443 |
| VascepaIcosapent Ethyl | 16 | $8,097 |
| ClopidogrelClopidogrel Bisulfate | 134 | $4,122 |
| Amiodarone Hcl | 76 | $3,014 |
| Rosuvastatin Calcium | 74 | $2,777 |
| Ezetimibe | 36 | $2,031 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $24 | $967,309961 claims |
| AstraZenecaFarxiga, Brilinta | $249 | $116,079125 claims |
| Boehringer IngelheimJardiance | $362 | $94,68394 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional cardiology providers in Hawaiion file to place this against a meaningful peer group, so we don't.
Other interventional cardiology in Honolulu
- John CoganHonolulu$82K
- Kris KawamotoHonolulu$25K
- Giselle Baquero CaranamaHonolulu$20K
- Atsushi TerakuboHonolulu$20K
- Kelly PaschkeHonolulu$7K
- John KaoHonolulu$6K
- John O'MaraHonolulu$5K
- Jay GadgilHonolulu$2K
- Marie NguyenHonolulu$189
- Jason CallWailuku$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.